Defining infection risk of bispecific antibodies for myeloma
Blood Adv
.
2024 Sep 24;8(18):4977-4978.
doi: 10.1182/bloodadvances.2024013813.
Author
Sarah P Hammond
1
Affiliation
1
Divisions of Infectious Diseases and Hematology/Oncology, Massachusetts General Hospital; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
PMID:
39316392
PMCID:
PMC11496961
DOI:
10.1182/bloodadvances.2024013813
No abstract available
Publication types
Comment
MeSH terms
Antibodies, Bispecific* / therapeutic use
Humans
Infections / etiology
Infections / immunology
Multiple Myeloma* / immunology
Substances
Antibodies, Bispecific